Drugs · acquisition-cost intelligence
Renvela
sevelamer carbonate· ingredient sevelamerDrugs for treatment of hyperkalemia and hyperphosphatemia· SEVELAMER CARBONATE 2400 mg/1; SEVELAMER CARBONATE 2.4 g/1; SEVELAMER CARBONATE 800 mg/1; SEVELAMER CARBONATE .8 g/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.22723
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-01-222026-05-20
Same-ingredient options by acquisition cost
Other sevelamer products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| sevelamer hydrochloride | $0.77349 | +$0.54630 |
| sevelamer hydrochloride | $0.77349 | +$0.54630 |
| sevelamer carbonate | $1.15 | +$0.92030 |
| SEVELAMER CARBONATE | $1.17 | +$0.94700 |
Medicare Part D coverage · CY2026
On 135 plan formularies · typical tier 4
Prior auth 33% · Step therapy 0% · Quantity limit 12% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.